Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix paediatric study
04-Mar-2015 -
Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia ...
Alprolix
Biogen Idec
hemophilia B
+1